Some Hemostatic Changes During the Course of Hemodialysis in Patients with Erythropoietin Treatment

Abstract

The recombinant human erythropoietin (rHuEPO), an effective agent in the treatment of renal anemia, can predispose chronic uremic patients to thrombotic events with regular hemodialysis (HD). It has been proposed that increased release of tissue plasminogen activator (t-PA) from endothelial cells, together with consumption of plasminogen activator inhibitor-1 (PAI- 1), is likely to be a leading cause of enhanced fibrinolytic activity (FA) during HD. In our study, rHuEPO-treated patients manifested PAI-1 Ag (antigen) plasma levels that were significantly augmented after HD, suggesting FA inhibition during the HD session. The elevated predialysis beta-thromboglobulin (BTG) and platelet factor-4 (PF-4) plasma levels were increased in rHuEPO-treated patients during HD; the platelet protein levels were simultaneously decreased in the control group. Both findings reflect decreased FA and greater activity of platelets in the course of HD with administration of rHuEPO and a possible correlation of these mechanisms with the questioned prothrombotic performance of rHuEPO. Key Words: Erythropoietin—Hentodiatysts—Fibrinotytic activity—Platelet proteins.

Get full access to this article

View all access options for this article.

References

Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin, quality of life and exercise capacity of patients receiving haemodialysis. BMJ 1990; 300:573-8.

Lundin AP Quality of life: subjective and objective improvement with recombinant human erythropoietin therapy. Semin Nephrol 1989 ;9:22.

Sundal E. , Kaeser U. Correction of anaemia of chronic renal failure with recombinant human erythropoietin: safety and efficacy of one year s treatment in a European multicentre study of 150 haemodialysis-dependent patients. Nephrol Dial Transplant 1989;4:979-87.

Eschbach JW , Abdulkadi MH , Browne JK Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase II multicenter clinical trial. Ann Intern Mod 1989;111:992-1000.

Moia M. , Mannuci PM , Vizzoto L. , et al. improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin. Lancet 1987;2:1227-9.

Van Geet C. , Hauglustaine D. , Verresen L. , et at. Haemostatic effects of recombinant human erythropoietin in chronic haemodialysis patients. Thromb Haemost 1989 ;61:117-21.

Tsao C. , Kao RH , Cheng TZ , et al. The effect of recombinant human erythropoietin on hemostatic status in chronic uremic patients. Int Hematol 1992;55:197-203.

Cases A. , Escolar R. , Reverter JC , et al. Recombinant human erythropoietin treatment improves platelet function in uremic patients. Kidney Int 1992 ;42:668-72.

Malyszko J. , Malyszko JS , Borawski J. , et al. A study of platelet functions, some hemostatic and fibrinolytic parameters in relation to serotonin in hemodialyzed patients under erythropoietin therapy. Thromb Res 1995;77:133-43.

10.

Aunsholt NA , Ahlbom G. , Steffensen G. , et al. Fibrinolytic capacity in hemodialysis patients treated with recombinant human erythropoietin . Nephron 1992;62:284-8.

11.

Macdougall IC , Davies ME , Hallett I. , et al. Coagulation studies and fistula blood flow during erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant 1991;6: 862-7.

12.

Carlini RG , Obialo CI. Rothstein M. Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients. Am J Hematol 1993;6:103-7.

13.

Tomura S. , Nakamura Y. , Tachibana K. , et al. Enhanced coagulation and fibrinolysis during treatment with recombinant human erythropoietin in patients undergoing chronic hemodialysis . Blood Purif 1993;11:370-7.

14.

Bellon JL , Castellanos C. , Acevedo L. , et al. Measurement of beta-thromboglobulin and platelet factor 4 to follow up patients with artificial heart valves. Semin Thromb Hemost 1993; 19:178-82.

15.

Nakamura Y. , Tomura S. , Tachibana K. , et al. Enhanced fibinolytic activity during the course of hetnodialysis. Clin Nephrol 1992;38:90-6.

16.

Van Hulstein H. , Van Es A. , Bertina R. , et al. Plasma beta-thromboglobulin and platelet factor 4 in renal failure. Thromb Res 1981 ;24:175-80.

17.

Depermann D. , Andrassy K. , Seeling H. , et al. Beta-thromboglobulin is elevated in renal failure without thrombosis. Thromb Res 1980;17-63-9.

18.

Kurihara Y. , Nakayama H. , Nakagawa S. Plasma beta-thromboglobulin and platelet factor 4 in renal insuficiency. Thromb Res 1980;18:557-60.

19.

Kubisz P. , Patizek M. , Seghier F. , et al. Relationship between platelet aggregation and plasma beta-thromboglobulin levels in arteriovascular and renal diseases. Atherosclerosis 1985; 55:363-8.